Medpace joins list of CROs attracting private equity investment

By Gareth Macdonald

- Last updated on GMT

Related tags Investment

New York-headquartered private equity investment group CCMP Capital will buy a majority stake in US CRO Medpace.

According to various reports​ CCMP will pay as much as $600m (€428m) for 80 per cent of the privately-owned Cincinnati, Ohio contract research organisation (CRO) with the management team retaining the remaining 20 per cent.

Medpace is just the latest in a growing list of CROs to attract private equity investment​, following hot on the heels of Omnicare​ which was acquired by Nautic Partners earlier this month.

The prevailing wisdom is that the wave of consolidation sweeping the sector - INC’s bid for Kendle​ and CliniPace’s move for PFC Pharma Focus​ being the most recent examples - is attractive to investors seeking a lucrative exit strategy in a few years time.

Support for this idea came last week when inVentiv Health announced plans to buy PharmaNet​ from private equity firm JLL Partners, which had owned the CRO since 2009.

CCMP did not respond to’s request for more information about its motivation for the Medpace deal.


In a press statement Medpace CEO August Troendle, who will remain in his post when the acquisition is completed next month, said the deal will give the CRO the financial clout to enact its growth strategy.

The transaction will provide resources to make the strategic long-term investments that are needed to advance our leadership position, grow the core the business and expand our global reach​.”

Medpace’s most recent investments were medical device trials firm Symbios Clinical​, in April 2010, and Germany-based​regulatory specialist Medical Consulting Dr Schlichtiger​ in January of that year.

The firm is also building a new 132,000 sq ft headquarters in Madisonville, Ohio near Cincinnati, which it said will create 760 new jobs when fully operational in 2014.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more